Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1407 • ACR Convergence 2023
Defining Thresholds of Presenteeism Measures for Unacceptable Work Participation in axSpA
Dafne Capelusnik¹, Sofia Ramiro², Elena Nikiphorou³, Walter P. Maksymowych⁴, Marina Nighat Magrey⁵, Helena Marzo-Ortega⁶ and Annelies Boonen⁷, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³King's College London, London, United Kingdom, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Case Western Reserve University, University Hospitals, Cleveland, OH, ⁶NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: Presenteeism is associated with lower work satisfaction and future sick leave in axial spondyloarthritis (axSpA). It is generally assessed as a continuous variable; however,…
Abstract Number: 2213 • ACR Convergence 2023
Identification of a Diagnostic Model for Axial Spondyloarthritis in Daily Clinical Practice Using a Random Forest Machine Learning Approach
Imke Redeker¹, Styliani Tsiami², Jan Eicker³, Uta Kiltz⁴, David Kiefer², Ioana Andreica⁵, Philipp Sewerin² and Xenofon Baraliakos⁶, ¹Ruhr Universität Bochum, Bochum, Germany, ²Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ³Rheumazentrum Ruhrgebiet Herne and Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: In axial spondyloarthritis (axSpA), early diagnosis plays a key role in preventing disease progression. However, a validated diagnostic algorithm does not exist, while classification…
Abstract Number: 0090 • ACR Convergence 2023
Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis
Addison Pacheco¹, Michael Tang¹, Sinead Maguire², Melissa Lim¹, Fataneh Tavasolian³, Zoya Qaiyum⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory disease that predominantly affects the spine and the sacroiliac joints. Dysregulation of Type 3 immunity has been implicated…
Abstract Number: 0531 • ACR Convergence 2023
Effects of Anti-tumor Necrosis Factor Treatment on Lipid Profiles in Patients with Ankylosing Spondylitis
Inbeom Kwon¹, bora nam², Nayeon Choi³, Ji-Hui Shin², Seunghun lee⁴ and Tae-Hwan Kim², ¹Department of Medicine, Hanyang University College of Medicine, Seoul, South Korea, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea, ⁴Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: To investigate the effects of anti-tumor necrosis factor (anti-TNF) treatment on lipid profiles and identify risk factors for elevated total cholesterol (TC) after the…
Abstract Number: 1385 • ACR Convergence 2023
Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers
Joerg Ermann¹, Stephanie Sinnappan² and Alexandra Forte³, ¹Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: Several sets of treatment recommendations for axial spondyloarthritis and ankylosing spondylitis (axSpA/AS) have been published. Clinical practice guidelines are not followed consistently by health…
Abstract Number: 1408 • ACR Convergence 2023
Impact of Disease Activity on Functional Impairment in Patients with Spondyloarthritis Is Different According to the Degree of Radiographic Progression: Result from SNUH-AS Cohort
Ji In Jung¹, Ju Yeon Kim², Jin Kyun Park³, Eun Young Lee³, Eun Bong Lee² and Jun Won Park², ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Seoul National University Hospital, Seoul, South Korea, ³Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: Although previous studies suggested that physical functioning is largely driven by disease activity in patients with spondyloarthritis (SpA), its relationship to radiographic progression has…
Abstract Number: 2214 • ACR Convergence 2023
Systematic Literature Review and Meta-analysis Informing the Development of 2023 Spondyloarthritis Research and Treatment Network (SPARTAN) Referral Recommendations for Axial Spondyloarthritis
Abhijeet Danve¹, Maureen Dubreuil², Swetha Ann Alexander³, Yuliya afinogenova⁴, Mohamad Bittar⁵, Alyssa Grimshaw⁶, Liana Fraenkel⁷, Michael LaValley⁸, Anand Kumthekar⁹, Jean liew¹⁰, Marina Nighat Magrey¹¹, Vikas Majithia¹², Sali Merjanah¹³, Hillary Norton¹⁴, Jessica A Walsh¹⁵ and Atul Deodhar¹⁶, ¹Yale University School of Medicine, Glastonbury, CT, ²Department of Rheumatology, Boston University School of Medicine, Milton, MA, ³University of Utah Health, Salt Lake City, UT, ⁴Yale, Hamden, CT, ⁵The University of Tennessee Health Science Center, Memphis, TN, ⁶Yale University, New Haven, CT, ⁷Berkshire Health Systems, Lenox, MA, ⁸Boston University School of Public Health, Arlington, MA, ⁹Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ¹⁰Boston University, Boston, MA, ¹¹Case Western Reserve University, University Hospitals, Cleveland, OH, ¹²Mayo Clinic Florida, Jacksonville, FL, ¹³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ¹⁴Inspire Santa Fe Rheumatology, Santa Fe, NM, ¹⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ¹⁶Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Lack of timely referral of suspected axSpA patients to rheumatologists contributes to misdiagnosis, delayed treatment, and poor outcomes. Currently there are no formal guidelines…
Abstract Number: 0092 • ACR Convergence 2023
Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion
Michael Tang¹, Zoya Qaiyum², Melissa Lim¹ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Sustained chronic inflammation in the spine and of the sacroiliac joints is a key feature in Ankylosing Spondylitis (AS). A central role of CTL…
Abstract Number: 0532 • ACR Convergence 2023
Factors Associated with Cause-specific Discontinuation of Long-term Anti-tumor Necrosis Factor Agent Use in Patients with Ankylosing Spondylitis
bora nam¹, Nayeon Choi², Bon San Koo³, Jiyeong Kim², Ji-Hui Shin¹, Seunghun lee⁴, kyung bin Joo⁴ and Tae-Hwan Kim¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea, ³Inje University Seoul Paik Hospital, Seoul, South Korea, ⁴Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Anti-tumor necrosis factor (TNF) agents have proven to be effective in treating Ankylosing spondylitis (AS). However, a significant number of patients discontinue or switch…
Abstract Number: 1386 • ACR Convergence 2023
Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis
Huseyin Berk Degirmenci¹, Christine E. Peloquin², Sara Lodi², Pedro Machado³, S. Reza Jafarzadeh⁴, Tuhina Neogi⁵, Lianne Gensler⁶, Maureen Dubreuil⁷ and Jean Liew², ¹St. Elizabeth's Medical Center, Boston, MA, ²Boston University, Boston, MA, ³Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁷Department of Rheumatology, Boston University School of Medicine, Milton, MA
Background/Purpose: Although current axial spondyloarthritis (axSpA) management guidelines do not address opioid use for chronic pain, available data show that opioid use is common among…
Abstract Number: 1409 • ACR Convergence 2023
Analysis of Soluble Biomarkers in Axial Spondyloarthritis
Caroline Bauchiero¹, Stephanie Sinnappan² and Joerg Ermann³, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Distinguishing patients with axial spondyloarthritis (axSpA) from patients with other causes of chronic back pain remains a challenge. The lack of reliable biomarkers contributes…
Abstract Number: 2219 • ACR Convergence 2023
Comparing the Construct Validity Among Measures of Pain and Stiffness in Patients with Axial Spondyloarthritis
Dafne Capelusnik¹, Elena Nikiphorou², Annelies Boonen³, Désirée van der Heijde⁴, Robert BM Landewé⁵, Astrid van Tubergen⁶ and Sofia Ramiro⁴, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²King's College London, London, United Kingdom, ³Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands
Background/Purpose: In the context of the recent update of the ASAS core outcomes set (COS), the preferred comparative validity of the measurement instruments to assess…
Abstract Number: 0202 • ACR Convergence 2023
Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
Tal Gazitt¹, Noa Hayat², Amir Haddad², Joy Feld³, Nili Stein², Idit Lavi², Ilan Feldhamer⁴, Arnon Dov Cohen⁵, Walid Saliba² and Devy Zisman², ¹Carmel Hospital, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel
Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
Abstract Number: 0535 • ACR Convergence 2023
Pharmacologic Treatment of Ankylosing Spondylitis in a Large Urban Medical Center: Effects of Socioeconomic Status, Race/Ethnicity and Sex
EA TROY¹, ZT Chan¹, WL GALLANTER², EM Adams³, Mina Al-Awqati² and Huan Chang¹, ¹University of Illinois at Chicago; Jesse Brown VA Medical Center, Chicago, IL, ²University of Illinois at Chicago, Chicago, IL, ³Jesse Brown VA Medical Center, Chicago, IL
Background/Purpose: Ankylosing spondylitis (AS) is estimated to affect up to 1,647,500 Americans, resulting in significant disability and lost productivity for affected individuals. Biologic medications reduce…
Abstract Number: 1390 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study
Asmir Vodencarevic¹, Jan Brandt-Juergens², Daniel Peterlik¹, Benjamin Gmeiner¹ and Uta Kiltz³, ¹Novartis Pharma GmbH, Nürnberg, Germany, ²rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients suffering from ankylosing spondylitis (AS) in randomized clinical trials [1]. There is only limited…

« Previous Page
1
…
8
9
10
11
12
…
62
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].